A nuclear shift of GSK3β protein is an independent prognostic factor in prostate cancer.
GSK3beta
immunohistochemistry
prognosis
prostate cancer
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
01 Mar 2019
01 Mar 2019
Historique:
received:
16
01
2019
accepted:
15
02
2019
entrez:
23
3
2019
pubmed:
23
3
2019
medline:
23
3
2019
Statut:
epublish
Résumé
Glycogen synthase kinase 3ß (GSK3ß) regulates many cancer relevant cellular processes and represents a potential therapeutic target. GSK3ß overexpression has been linked to adverse tumor features in many cancers, but its role in prostate cancer remains uncertain. We employed immunohistochemical GSK3ß expression analysis on a tissue microarray with 12,427 prostate cancers. Cytoplasmic and nuclear GSK3ß staining was separately analyzed. GSK3ß staining was absent in normal prostate epithelium, whereas 57% of 9,164 interpretable cancers showed detectable GSK3ß expression. Cytoplasmic staining was considered weak, moderate, and strong in 36%, 19.5% and 1.5% of tumors and was accompanied by nuclear GSK3ß staining in 47% of cases. Cytoplasmic GSK3ß staining as well as nuclear GSK3ß accumulation was associated with advanced tumor stage, high Gleason grade, presence of lymph node metastasis and early biochemical recurrence (
Identifiants
pubmed: 30899444
doi: 10.18632/oncotarget.26739
pii: 26739
pmc: PMC6422199
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1729-1744Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST The authors declare no financial conflicts of interest.
Références
EMBO J. 2000 Oct 16;19(20):5483-91
pubmed: 11032815
J Biol Chem. 2001 Jul 27;276(30):28586-97
pubmed: 11382772
Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):7951-5
pubmed: 12048243
J Cell Sci. 2003 Feb 15;116(Pt 4):637-46
pubmed: 12538764
Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24
pubmed: 12781368
J Biol Chem. 2003 Dec 19;278(51):51606-12
pubmed: 14563837
Endocrinology. 2004 Jun;145(6):2941-9
pubmed: 14988390
J Biol Chem. 2004 Jul 30;279(31):32444-52
pubmed: 15178691
Oncogene. 2004 Oct 14;23(47):7882-92
pubmed: 15361837
Biochem Soc Trans. 2004 Nov;32(Pt 5):803-8
pubmed: 15494020
Cancer. 2005 Jan 1;103(1):68-75
pubmed: 15573369
J Biol Chem. 2005 Mar 25;280(12):11740-8
pubmed: 15647282
Science. 2005 Oct 28;310(5748):644-8
pubmed: 16254181
Oncogene. 2006 Jan 19;25(3):329-37
pubmed: 16421604
Exp Mol Med. 2006 Feb 28;38(1):1-10
pubmed: 16520547
J Biol Chem. 2006 May 26;281(21):14841-51
pubmed: 16551619
Clin Cancer Res. 2006 Sep 1;12(17):5074-81
pubmed: 16951223
Adv Anat Pathol. 2006 Sep;13(5):238-46
pubmed: 16998317
BMC Cell Biol. 2007 Aug 14;8:34
pubmed: 17697341
Cancer Res. 2007 Sep 15;67(18):8504-10
pubmed: 17875689
J Neurochem. 2008 Mar;104(6):1433-9
pubmed: 18088381
Oncogene. 2008 Jun 5;27(25):3546-55
pubmed: 18223684
Neoplasia. 2008 Jun;10(6):624-34
pubmed: 18516299
Mod Pathol. 2008 Nov;21(11):1371-8
pubmed: 18552821
Mod Pathol. 2009 Jun;22 Suppl 2:S60-9
pubmed: 19494854
Anticancer Res. 2009 Jun;29(6):2077-81
pubmed: 19528467
J Cell Biochem. 2010 Apr 15;109(6):1192-200
pubmed: 20127713
Clin Cancer Res. 2010 Mar 1;16(5):1553-60
pubmed: 20179235
Hum Pathol. 2010 Sep;41(9):1255-64
pubmed: 20447678
Cancer Cell. 2010 Jul 13;18(1):11-22
pubmed: 20579941
Clin Cancer Res. 2010 Nov 1;16(21):5124-32
pubmed: 20889919
Cancer Prev Res (Phila). 2011 Sep;4(9):1495-506
pubmed: 21680704
Clin Cancer Res. 2011 Sep 15;17(18):5878-88
pubmed: 21791629
PLoS One. 2011;6(9):e25315
pubmed: 21980423
Mol Cell Biol. 2012 Jan;32(2):288-96
pubmed: 22064483
BMC Cancer. 2011 Dec 05;11:507
pubmed: 22142399
Eur Urol. 2012 May;61(5):1019-24
pubmed: 22336380
Int J Cancer. 2012 Sep 15;131(6):E872-83
pubmed: 22539113
Am J Pathol. 2012 Aug;181(2):401-12
pubmed: 22705054
N Engl J Med. 2012 Jul 19;367(3):203-13
pubmed: 22808955
N Engl J Med. 2012 Jul 19;367(3):270-1
pubmed: 22808963
Breast Cancer Res Treat. 2012 Nov;136(1):161-8
pubmed: 22976805
Mol Cells. 2012 Oct;34(4):375-82
pubmed: 23104438
Cancer Cell. 2013 Feb 11;23(2):159-70
pubmed: 23410972
BJU Int. 2013 May;111(5):753-60
pubmed: 23464824
Cancer Res. 2013 May 1;73(9):2795-805
pubmed: 23492366
Histopathology. 2013 May;62(6):899-907
pubmed: 23551536
J Pathol. 2013 Sep;231(1):130-41
pubmed: 23794398
Cancer Res. 2013 Oct 1;73(19):6068-79
pubmed: 23913826
Eur J Cancer. 2014 Mar;50(4):852-61
pubmed: 24380696
PLoS One. 2014 Mar 11;9(3):e91231
pubmed: 24618715
Oncotarget. 2014 May 30;5(10):2881-911
pubmed: 24931005
J Carcinog Mutagen. 2013 Aug 16;4(3):147
pubmed: 24944842
Oxid Med Cell Longev. 2014;2014:241864
pubmed: 25002914
Onco Targets Ther. 2014 Jun 25;7:1159-68
pubmed: 25028561
Oncotarget. 2014 Sep 30;5(18):8173-87
pubmed: 25327559
J Biol Chem. 2015 Jan 16;290(3):1348-63
pubmed: 25468908
Mol Cancer. 2015 Feb 03;14:20
pubmed: 25645517
Eur Urol. 2016 Apr;69(4):592-598
pubmed: 26542947
J Pathol Transl Med. 2016 Nov;50(6):411-418
pubmed: 27809448
Clin Cancer Res. 2017 Apr 15;23(8):1891-1897
pubmed: 28053024
Oncotarget. 2017 May 16;8(20):33972-33989
pubmed: 28430641
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Med. 1998 Jul;4(7):844-7
pubmed: 9662379
J Clin Pathol. 1998 May;51(5):370-4
pubmed: 9708203
Genes Dev. 1998 Nov 15;12(22):3499-511
pubmed: 9832503